Neratinib and ruxolitinib for metastatic triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This early-phase trial tests a combination of two targeted drugs, neratinib and ruxolitinib, for people with metastatic triple-negative breast cancer who have already had standard chemotherapy. The goal is to see if the combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have metastatic triple-negative breast cancer (cancer that has spread to other parts of the body).
- You have had standard chemotherapy before (like anthracycline, cyclophosphamide, or taxane), unless you couldn't have anthracycline due to a heart issue.
- You have not had more than 4 different chemotherapy treatments for metastatic cancer.
- You are generally healthy enough to be up and about (ECOG performance status 0-1).
- You are willing and able to have a small biopsy of your cancer (from the breast, chest wall, lungs, or liver, or a skin biopsy if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new treatment plan for people with metastatic triple-negative breast cancer that has already been treated with standard chemotherapy. It aims to see how well the combination works and whether it’s safe.
This trial tests a combination of tamoxifen (a hormonal therapy) and pegylated liposomal doxorubicin (a type of chemotherapy) for people with triple negative breast cancer that has spread or cannot be removed by surgery. It aims to see if this combination can help people whose cancer has not responded to at least two prior treatments.
This trial tests a combination of three drugs for advanced breast cancer that is both hormone-receptor-positive and HER2-positive, and has stopped responding to a newer targeted therapy called T-DXd. The goal is to see if this new combo can shrink tumors or slow their growth.
This trial tests a combination of four drugs—two immunotherapies (QL1706), an anti-angiogenic agent (anlotinib), and chemotherapy (nab-paclitaxel)—as a first-line treatment for advanced triple-negative breast cancer. The goal is to see if this combination slows or stops cancer growth better than standard treatment alone.
This trial tests a new immunotherapy drug (cadonilimab) combined with a chemotherapy (eribulin) against chemotherapy alone for triple-negative breast cancer that has come back or spread. If you receive the combination, the goal is to see if it helps control the cancer better or for longer.
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Hear when a new Metastatic Triple-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.